Lakewood-Amedex Biotherapeutics (LABT)

The company’s lead programme is Nu-3, a topical antimicrobial gel being evaluated for mildly infected diabetic foot ulcers. Diabetic foot infections are a serious complication of diabetes and can be difficult to treat because wounds may heal slowly and are vulnerable to resistant bacteria. By delivering the therapy directly to the infected area, Lakewood-Amedex aims to provide a targeted approach for a condition with meaningful medical need.

Beyond Nu-3, the company is developing additional candidates from the Bisphosphocin platform. Its early-stage pipeline includes potential treatments for complicated urinary tract infections and pulmonary infections, both of which represent large areas of concern for hospitals, physicians and public health systems due to the spread of antimicrobial resistance.

Lakewood-Amedex remains at the development stage, so its value is closely linked to clinical trial progress, regulatory outcomes and the ability to demonstrate safety and efficacy in defined infection settings. The company is positioned within the wider biotechnology effort to replenish the antibiotic pipeline, an area that has become increasingly important as pathogens such as MRSA and VRE limit the effectiveness of existing therapies.